Literature DB >> 2226399

Ultrastructural findings in horses with chronic obstructive pulmonary disease (COPD). I: Alterations of the larger conducting airways.

F J Kaup1, W Drommer, E Deegen.   

Abstract

Extensive light and electron microscope studies of the conducting airways were carried out in 28 horses with varying degrees of clinically manifested chronic obstructive pulmonary disease (COPD) and in 8 horses with normal lungs. The principal ultrastructural changes were found in the ciliated cells. There was focal loss of ciliated cells, which were replaced by undifferentiated cells in a largely hyperplastic epithelium, and some horses, independent of the degree of severity of the disease, showed various types of ciliary malformation. The finding of dilated intercellular clefts and accumulations of mast cells was interpreted as morphological evidence of non-specific mucosal hyperreactivity. Interstitial cells with intracytoplasmal crystal inclusions, the cause of which is not clear, were seen in many horses. Comparison between the clinical diagnosis and the morphological findings showed partial correlation. The ciliary loss, the appearance of peribronchial inflammatory processes and the occurrence of intracytoplasmic crystalline inclusions showed a positive correlation. In 12 of 28 cases, the severity of clinical diagnosis agreed with the degree of the morphological findings. The changes in the conducting airways were interpreted pathogenetically as reactive processes to changes in the small airways in the course of equine COPD.

Entities:  

Mesh:

Year:  1990        PMID: 2226399     DOI: 10.1111/j.2042-3306.1990.tb04287.x

Source DB:  PubMed          Journal:  Equine Vet J        ISSN: 0425-1644            Impact factor:   2.888


  9 in total

1.  Endothelin receptor alterations in equine airway hyperreactivity.

Authors:  Changaram S Venugopal; Sumanth Polikepahad; Earnestine P Holmes; John Vanden Heuvel; Tara L Leas; Rustin M Moore
Journal:  Can J Vet Res       Date:  2006-01       Impact factor: 1.310

2.  Chronic obstructive pulmonary disease: Usefulness of clinical signs, bronchoalveolar lavage, and lung biopsy as diagnostic and prognostic aids.

Authors:  J M Naylor; E G Clark; H M Clayton
Journal:  Can Vet J       Date:  1992-09       Impact factor: 1.008

3.  Neurokinin receptors in recurrent airway obstruction: a comparative study of affected and unaffected horses.

Authors:  Changaram S Venugopal; Earnestine P Holmes; Sumanth Polikepahad; Susan Laborde; Michael Kearney; Rustin M Moore
Journal:  Can J Vet Res       Date:  2009-01       Impact factor: 1.310

Review 4.  Pulmonary Remodeling in Equine Asthma: What Do We Know about Mediators of Inflammation in the Horse?

Authors:  Ann Kristin Barton; Heidrun Gehlen
Journal:  Mediators Inflamm       Date:  2016-12-07       Impact factor: 4.711

5.  Sequence variant analysis of RNA sequences in severe equine asthma.

Authors:  Laurence Tessier; Olivier Côté; Dorothee Bienzle
Journal:  PeerJ       Date:  2018-10-11       Impact factor: 2.984

6.  Development of a Semiquantitative Histological Score for the Diagnosis of Heaves Using Endobronchial Biopsy Specimens in Horses.

Authors:  M Bullone; P Hélie; P Joubert; J-P Lavoie
Journal:  J Vet Intern Med       Date:  2016-08-16       Impact factor: 3.333

7.  Metalloproteinases and their inhibitors are influenced by inhalative glucocorticoid therapy in combination with environmental dust reduction in equine recurrent airway obstruction.

Authors:  Ann Kristin Barton; Tarek Shety; Angelika Bondzio; Ralf Einspanier; Heidrun Gehlen
Journal:  BMC Vet Res       Date:  2016-12-09       Impact factor: 2.741

8.  Airway remodeling in horses with mild and moderate asthma.

Authors:  Amandine Bessonnat; Pierre Hélie; Carolyn Grimes; Jean-Pierre Lavoie
Journal:  J Vet Intern Med       Date:  2021-12-08       Impact factor: 3.333

Review 9.  The Immune Mechanisms of Severe Equine Asthma-Current Understanding and What Is Missing.

Authors:  Joana Simões; Mariana Batista; Paula Tilley
Journal:  Animals (Basel)       Date:  2022-03-16       Impact factor: 2.752

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.